<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01168505</url>
  </required_header>
  <id_info>
    <org_study_id>NP 002/2009 - CEP 543/09</org_study_id>
    <nct_id>NCT01168505</nct_id>
  </id_info>
  <brief_title>Iron Supplement in the Prevention of Anemia in Female Breast Cancer Patients</brief_title>
  <official_title>The Role of Intravenous Iron to Prevent Anemia in Women With Breast Cancer Receiving (Neo)Adjuvant Chemotherapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Instituto do Cancer do Estado de São Paulo</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Fundação Faculdade de Medicina</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Instituto do Cancer do Estado de São Paulo</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Study to evaluate the efficacy of intravenous iron supplementation in the prevention of
      anemia in patients receiving (neo)adjuvant breast cancer regimens.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>May 2010</start_date>
  <completion_date type="Anticipated">December 2014</completion_date>
  <primary_completion_date type="Anticipated">December 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Evaluate the efficacy of intravenous iron supplementation in the prevention of anemia in patients receiving (neo)adjuvant breast cancer regimens</measure>
    <time_frame>18 weeks</time_frame>
    <description>Anemia prevention defined by hemoglobin levels</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>no iron supplentation</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>iron supplement</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ferric hydroxide saccharate</intervention_name>
    <description>single dose of 200 mg (2 ampoules), 24-48 hours after administration of chemotherapy for a total of four doses</description>
    <arm_group_label>iron supplement</arm_group_label>
    <other_name>NORIPURUM</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Women older than 18 years

          2. Patient with operated breast cancer with indication for (NEO)adjuvant therapy

          3. They must have hemoglobin levels within the normal range (&gt; 12g/dL), absence of renal
             and hepatic dysfunction as assessed by serum levels of urea, creatinine, AST, ALT.

          4. Lack of folic acid deficiency and vitamin B12

          5. Able to provide written informed consent.

        Exclusion Criteria:

          1. Use of any oral supplement containing iron;

          2. Patients who have iron overload as defined by serum ferritin&gt; 800 microg / L or
             transferrin saturation&gt; 40%;

          3. Patients who are pregnant or breastfeeding;

          4. History of active infection or active bleeding except menstruation;

          5. History of HIV or hepatitis B or C - clinically important; -
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Paulo Hoff, MD Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Instituto do Câncer do Estado de São Paulo</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>PAULO HOFF, MD Prof.</last_name>
    <phone>++55-11-38932619</phone>
    <email>juliana.paula@icesp.org.br</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>ROBERTO ARAI, Pharm PHD</last_name>
    <phone>++55-11-38932619</phone>
    <email>roberto.arai@icesp.org.br</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Instituto Do Cancer Do Estado de São Paulo</name>
      <address>
        <city>São Paulo</city>
        <state>SP</state>
        <zip>01246-000</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>MAX MANO, MD PHD</last_name>
      <phone>55-11-38932646</phone>
      <email>elaine.longo@icesp.org.br</email>
    </contact>
    <investigator>
      <last_name>Aknar Calabrich, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Sirio Libanes</name>
      <address>
        <city>São Paulo</city>
        <zip>01308-000</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>PAULO HOFF, MD</last_name>
      <phone>++55-11-3155-0995</phone>
      <email>rosana.batista@hsl.org.br</email>
    </contact>
    <investigator>
      <last_name>PAULO HOFF, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>AKNAR CALABRICH, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 21, 2010</study_first_submitted>
  <study_first_submitted_qc>July 22, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 23, 2010</study_first_posted>
  <last_update_submitted>May 20, 2014</last_update_submitted>
  <last_update_submitted_qc>May 20, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 21, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Iron</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

